Apr 17, 2019 | By Thomas
French biotechnology company Poietis has announced the granting of a third patent for its laser-assisted 3D bioprinting technology.
"We were the first to explore the industrial potenfial of laser assisted bioprinting technology in various applications. The granting of this series of European patents further supports Poiefis’ position in the field of 3D bio-printing," stated Fabien Guillemot, President and CEO of Poietis.
Based on its expertise in bioprinting technologies and in particular high resolution laser bioprinting, Poietis has also developed the multimodal bioprinting platform NGB (Next Generation Bioprinting). The NGB platform aims to give tissue engineers and researchers greater freedom in the choice of biomaterials and hydrogels. Winner of the 2014 ILab Contest (French National Competition for Innovative start-up Creation of the Ministry of Research, Creation-Development category) and the 2016 Worldwide Innovation Contest, Poietis' laser-assisted 3D bioprinting technology us initially developed at the INSERM and Bordeaux University. The laser-assisted bioprinting technology can position cells in 3D with extremely high cellular resolution (on the order of ten microns) and cellular viability (over 95%).
In 2015, BASF signed an agreement with Poietis to use their technology for research and development purposes. Both companies are looking at ways of applying Poietis’ bioprinting technology to BASF’s existing processes in an effort to improve the company’s skin equivalent model Mimeskin. Poietis has also partnered with Servier Laboratories to create 4D printed liver toxicity detection device.
Most recently, the company has announced its 4D bioprinting platform, an automated robotic system to improve the standardization of manufacturing processes and the functionality of biological tissues.
The latest patent issued by the European Patent Office, Patent No. EP3233499, is entitled “Laser printing method and device for implementing said method.” It follows the 2017 Patent No. EP2542659 entitled “Bioprinting Station, assembly comprising such bioprinting station and bioprinting method” which relates to the adaptation of the printing patterns on substrates; and 2018 Patent No. EP3234102 entitled “Method for laser printing biological components and device for implementing said method”, which covers the laser-assisted bioprinting and multimodal bioprinting processes in Europe.
“The grant of these patents strengthens Poietis’ intellectual property asset,” explained Bruno Brisson, General Manager and VP Business Development at Poietis. “It is also additional protection of important technological bricks that are integrated into the NGB-R, next-gen bioprinting systems that we commercialize now.”
Posted in 3D Printer Company
Maybe you also like:
- GE Research uses 3D printing to design Ultra Performance Heat Exchanger
- Tel Aviv University scientists 3D print a tiny live heart using patient’s own cells
- University of South Australia designs 3D printed feet that mimic diabetic foot wounds
- AREVO to manufacture 3D printed carbon fibre unibody frames for Emery ONE eBike
- Arabtec Construction signs MOU to establish 3D Concrete Printing hub at American University in Dubai
- New technique uses ultrasound to align living cells in 3D bioprinted tissues
- COS and Arthur Mamou-Mani present 3D printed bioplastic Conifera pavilion in Milan
- Samsung's Galaxy S10 fingerprint sensor tricked by 3D printed fingerprint
- Virginia Tech researchers integrate sensors into personalised 3D printed prosthetics
- Researchers 3D print metamaterials with unique microwave or optical properties